A369 effi cacy of VSL#3 (all doses) comparing to placebo and slightly more effective for VSL#3 (6 g/day) comparing to placebo with RR of 20.35 with a 95% CI of 6.16-67.22 (P < 0.0001). Effi cacy of antibiotics comparing to placebo showed a summary RR of 2.68 with a 95% CI of 0.4-17.99 and P = 0.3107 for clinical improvement in three trials. The summary RR for effi cacy of ciprofl oxacin comparing to metronidazole was 0.68 with a 95% CI of 0.44-1.06 (P = 0.8913). CONCLUSIONS: In conclusion, alongside the benefi t of probiotics and antibiotics in the management of pouchitis, effects of probiotics and antibiotics on pouchitis vary according to different mixtures of microorganisms strains in probiotics and different spectrums of antibiotics. OBJECTIVES: To evaluate the prevalence and incidence of hepatitis a in a managed care population, segmented by a range of characteristics including age, gender, geography, and health insurance plan. METHODS: This was an observational retrospective cohort study utilizing medical and pharmacy claims data for January 1, 2005 through December 31, 2008 from the Impact National Managed Care Database (Benchmark Database). The index date was defi ned as the date of the fi rst and only diagnostic claim for hepatitis a within the intake period. All prevalence results reported below are per 100,000 and incidence is presented as per person years. RESULTS: Out of a total of 94,985,124 subjects in the database, females and males were represented equally (51% and 49% respectively). The 45-64 year age group had the greatest percentage of subjects. The prevalence of hepatitis a among men and women were almost equal (9 and 8, respectively). The 45-54 years age group had the highest hepatitis a prevalence (4) followed by the 25-34, 35-44, and 55-64 age groups (3 for each group). The largest hepatitis a prevalence rate was from the northeast region (7) followed by the south (6). In the 2005-2008 timeframe, hepatitis a prevalence was similar in each year (4). Incidence rates across age, region and specifi c zip codes in person years were less than 1 person per year. The incidence was slightly higher in males. Among three digit zip codes, the zip codes "100" showed higher incidences each year with higher prevalence. CONCLUSIONS: In a large commercially insured US population, we observed similar prevalence rates of hepatitis a for males and females. The disease was most prevalent in the 45-54 years age group. The northeast had the highest prevalence rate from 2005-2008. 
GASTROINTESTINAL DISORDERS -Cost Studies PGI5 A BUDGET IMPACT ANALYSIS OF THE HEPATITIS C TREATMENT WITH PEGYLATED INTERFERON IN BRAZIL
Fonseca M, Araújo GTBD AxiaBio, São Paulo, Brazil OBJECTIVES: Cost-effectiveness analyses of new hepatitis C drugs have been used to select and approve drugs that should be fi nanced by the public health care system. However there are still a huge amount of uncertainties within these studies. The fact of having pharmacoeconomic and budget impact data of these new pharmacological alternatives will help to select the most effi cient alternative. With this, the objective is to perform a budget impact analysis (BIA) of the treatment with pegylated interferon (pegIFN), alfa-2a or alfa-2b, plus ribavirin in, economically active genotype I patients, aging from 30 to 59 years, with chronic hepatitis C (CHC). METHODS: An interactive model has been designed from the inputs obtained from the medical literature. Both strategies have been considered as therapeutic equivalents, without signifi cative difference in side effects, and as having the same price. RESULTS: The number of patients with CHC evaluated in the model has been of 355,611, 15.2% between 30 and 39 years, 13% between 40 and 49 years and 9% between 50 and 59 years, mimicking the Brazilian population and with an average weight of 70.6 kg. The duration of treatment was 48 weeks, with virologic response measured in weeks 2.4,12.24 and 48. a total of 91% and 99.8% of the patients receiving pegIFN alfa-2a or alfa-2b, respectively achieved sustained virological response at 72 weeks. Total cost was R$ 4,012,531,131.29 and R$3,752,238,973.99 for the treatment with pegIFN alfa-2a + RIB and pegIFN alfa-2b + RIB, respectively. CONCLUSIONS: Although cost-effectiveness analysis appears to be favorable to pegIFN alfa-2a + RIB, a BIA seems to favour pegIFN alfa-2b + RIB due to its better predictability in the 12 nd week of treatment. In this case, the treatment with pegIFN alfa-2b + RIB (in comparison with pegIFN alfa-2a + RIB) is an effi cient strategy.
PGI6

COST-EFFECTIVENESS OF MR ELASTOGRAPHY FOR DIAGNOSING LIVER FIBROSIS: PRELIMINARY THRESHOLD ASSESSMENT
Lee DW 1 , Palathinkara V 1 , Dekoven M 2 1 GE Healthcare, Waukesha, WI, USA; 2 IMS Health, Falls Church, VA, USA OBJECTIVES: MR Elastography (MRE) is a non-invasive test under clinical trial evaluation for effectiveness in helping diagnose liver fi brosis. This study estimated the accuracy needed for MRE to be cost-neutral from a US payer's perspective.
METHODS:
We constructed a decision-analytic model comparing diagnostic costs under two scenarios for patients with suspected liver fi brosis: 1) biopsy, or 2) MRE followed by biopsy when the MRE test was positive. We conducted a targeted litera-ture review and consulted with a leading hepatologist and pathologist to identify the appropriate procedure codes associated with liver biopsy; we assumed MRE would be reimbursed using CPT-4 code 74,181 (magnetic resonance (eg., proton) imaging, abdomen; without contrast material(s)). We assigned the appropriate allowable charges to the identifi ed procedure codes using the 2010 Medicare Physician Fee Schedule. Finally, we assumed negative predictive values (NPV) of 0.8, 0.9 and 0.95, and that patients with a false-negative MRE ultimately received a biopsy. RESULTS: The cost of a liver biopsy was $1424 (ultrasound $164, surgical $881, pathology $347, laboratory $32) and the cost of an MRE (without contrast) was $946 (hospital setting) or $666 (non-hospital setting). In a hospital setting, MRE is potentially cost saving if the test-negative rate is greater than 83%, 74% and 70% for NPVs of 0.8, 0.9 and 0.95, respectively. In a non-hospital setting, MRE can reduce diagnostic costs when more than 58%, 52% and 49% or patients have negative MRE results for the corresponding NPV values. CONCLUSIONS: The cost of liver biopsy is substantial as compared to MRE. MRE offers the potential of reducing the cost of diagnosing liver fi brosis by avoiding unnecessary biopsies. Cost saving potential increases with MRE's negative predictive value and negative test rate.
PGI7 ECONOMIC BURDEN OF OPIOID INDUCED CONSTIPATION IN SPAIN
Guijarro P 1 , Alonso-Babarro A 2 , Viqueira A 1 , Fernandez G 1 1 Pfi zer Spain, Alcobendas, Madrid, Spain; 2 La Paz Hospital, Madrid, Spain OBJECTIVES: To analyze the use of health care resources and the associated costs in patients with opioid induced constipation (OIC). METHODS: An observational, retrospective, multicenter study was carried out in Spanish National Health System hospitals. All patients were free of constipation at baseline and received opioids for at least 2 months. In order to determine patient resource utilization, a review of the patient records and patient-interviews were performed to all patients diagnosed with OIC. Patients were evaluated depending on response to oral treatment for OIC. The observation period was 2 months. The unit costs were obtained from Spanish databases (c 2009). RESULTS: A total of 744 patients were included. Patients had a mean (SD) age of 64.2 (13.4) and 48% were male. During the study period, 46.6% of the patients developed OIC. Most of these were treated fi rst with oral laxatives exclusively (67.7%), 63.8% responded to the treatment and 36.2% did not. Of the total number of patients with OIC, 61.5% required a visit to health care services. Forty-four patients required a visit to the Emergency Room (ER) and 26 were hospitalized with a median length of stay of 3 days. Overall mean total cost (SD) of constipation management was c271.08 (c621.22). Resource utilization in responders to oral laxatives was statistically signifi cant lower than in non-responders. a higher percentage of non-responders required health care visits, ER visits, and hospitalizations (P < 0.001). The mean cost (SD) for each responder was c115 (c230) compared to c442 (c810) for each non-responder (P < 0.001). CONCLUSIONS: OIC increases health care resource utilization particularly in patients with a poor response to oral laxatives. The economic burden of OIC was 3.8 times higher in non-responders than in responders.
PGI8 HIDDEN COSTS OF ROTAVIRUS DISEASE-A RETROSPECTIVE MATCHED ANALYSIS OF HOSPITAL EPISODE STATISTICS (HES) DATA
Morgan C 1 , Adlard NE 2 , Carroll SM 2 1 Cardiff Research Consortium Ltd, CARDIFF, UK; 2 Sanofi Pasteur MSD, Maidenhead, UK OBJECTIVES: To determine the impact of rotavirus (RV) disease as a secondary diagnosis on hospital length of stay (LOS) and cost for children under fi ve years of age in England. METHODS: The study was based on Hospital Episodes Statistics for England 2001-2007 using a matched cohort design. Admissions with a secondary diagnosis of RV were extracted and matched by age, year of admission and, where relevant, therapeutic procedure, to other admissions from HES with the same primary diagnosis. Primary admissions were classifi ed as potentially related or unrelated to RV. LOS was compared using the paired Wilcoxon test. RESULTS: Of 2126 admissions with a secondary diagnosis of RV, 707 (33.3%) had no other secondary diagnoses. Of these, 385 admissions were matched for primary diagnosis to controls. Median LOS for admissions was 2.0 days (Inter-Quartile Range [IQR] 1.0-4.0), mean (sd) 3.2 (4.1) compared with median 1.0 (IQR 0.0-1.5), mean 1.4 (sd 3.5) for control admissions (p-value < 0.001). Median cost/admission was £771 (IQR £604-£1090), mean cost was £1105 (sd £1064) compared with median £650 (IQR £564-£1090), £902 (sd 1004) (p-value < 0.001). a total of254/385 admissions were defi ned as unrelated to RV. For these admissions, median LOS was 2.0 days (IQR 1.0-4.25), mean 3.7 (sd 4.5) compared with median 1.0 (IQR 0.0-2.0), mean 1.6 (sd 4.0) for control admissions (p-value < 0.001). Median cost/admission was £918 (IQR £564-£1090), mean £1132, (sd £1132) compared with median £771 (IQR £564-£1090), mean £980 (sd £1187), (p-value < 0.001). CONCLUSIONS: As a secondary diagnosis in HES, RV has a signifi cant incremental impact on LOS and cost. Variations in testing and reporting of RV mean that HES data may signifi cantly under represent the overall burden of RV disease. This implies that standard modelling methodologies may underestimate the true burden of RV disease in the context of health care acquired infection.
